Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

About this update from Iridex Corporation

[{"type":"image","alt":"IRIDEX Corporation","displaySize":"","headline":null,"caption":"IRIDEX Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/ffe273cdb8e913085b9d4a020e219250"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r51WXqBBd3BbgLab_DBobg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ffe273cdb8e913085b9d4a020e219250","width":300,"height":90}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.1","length":580,"tagName":"p"},{"type":"text","content":"The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The study included 76 eyes from patients with moderate to advanced glaucoma who underwent retreatment following variable responses to their primary procedure. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment.","length":541,"tagName":"p"},{"type":"text","content":"“These findings support retreatment with MicroPulse TLT as a valuable option in glaucoma care, particularly for patients who experienced an initial IOP-lowering benefit that diminished over time,” said lead author Dr. Ronald de Crom. “The results also indicate that long-term success and repeatability is most favorable in patients who responded to the primary treatment, helping clinicians better identify candidates for retreatment.”","length":435,"tagName":"p"},{"type":"text","content":"Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On ...

More updates from Iridex Corporation